Oxford Immune Algorithmics

OIA is a top AI company using innovative technology for personalized healthcare and disease prevention.

General Information
Company Name
Oxford Immune Algorithmics
Founded Year
2018
Location (Offices)
Founders / Decision Makers
Number of Employees
-
Industries
-
Funding Stage
-
Social Media

Oxford Immune Algorithmics - Company Profile

Oxford Immune Algorithmics (OIA) is a groundbreaking AI company that specializes in immune monitoring and personalized healthcare solutions. Established in 2018 by the University of Oxford, OIA utilizes advanced AI technology to revolutionize disease prevention and eradication. With its innovative approach, the company aims to tailor healthcare strategies to individual immune profiles, ultimately mitigating preventable diseases on a global scale. OIA's commitment to leveraging cutting-edge technology for the betterment of public health positions it as a top contender in the AI and healthcare industries.

Taxonomy: personalized healthcare, disease prevention, Oxford Immune Algorithmics, immune monitoring, University of Oxford, cutting-edge technology, preventable diseases, healthcare solutions

Funding Rounds & Investors of Oxford Immune Algorithmics (0)

View All

There is no investment information

Similar Companies to Oxford Immune Algorithmics

View All
Pathios Therapeutics - Similar company to Oxford Immune Algorithmics
Pathios Therapeutics Using human genetics to transform cancer outcomes
epicombi.ai - Similar company to Oxford Immune Algorithmics
epicombi.ai Targeting epigenetically induced tumour loss of identity and immune masking with AI-discovered, network-acting drugs
OXFORD VACMEDIX UK LIMITED - Similar company to Oxford Immune Algorithmics
OXFORD VACMEDIX UK LIMITED Developing therapeutic cancer vaccines using ROP technology
AnTolRx - Similar company to Oxford Immune Algorithmics
AnTolRx Innovative therapies for autoimmune diseases through targeted immune-regulation using proprietary nanoparticle-based solutions.
ImmunoGenesis, Inc. - Similar company to Oxford Immune Algorithmics
ImmunoGenesis, Inc. Re-envisioning cold tumor treatment. Our deliberate drug development strategy targets mechanisms of immune resistance.